Glenmark Pharmaceuticals Inc., USA launches Methylene Blue Injection USP, 50 mg/10mL (5 mg/mL) Single-Dose vial
Glenmark launches Winlevi (clascoterone) 10 mg/g cream in Key European Markets for the Treatment of Acne Vulgaris
Please find attached Investor Presentation to be made at Glenmark Pharmaceuticals Limited Investor Day 2026 today.
Transcript of the Earnings call has been uploaded on Company's website
Glenmark Pharmaceuticals Inc., USA launches Lacosamide Injection USP, 200 mg/ 20mL (10 mg/mL), Single-Dose Vials
We have uploaded Audio Recording of Q4 FY 2025-26 Earnings Call held on June 01, 2026 on the website of the Company.
Investor Presentation - Q4 FY 25-26
Press Release and Management Discussion & Analysis for the Fourth Quarter ended March 31, 2026
The Board of the Company at its meeting held today has approved the transfer of the Company's Nebulizer brands/ IP portfolio to Glenmark Healthcare Limited, a wholly owned subsidiary.
The Board at its meeting held today i.e. May 29, 2026 have approved Early Retirement of Company Secretary & Compliance Officer, Appointment of Company Secretary & Compliance Officer and Appointment of Senior Management Personnel.
| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 3,207.38 | 2,506.70 | 3,062.95 | 3,244.19 | 3,433.80 | 3,387.55 | 3,256.21 | 3,264.44 | 6,046.87 | 3,900.62 | 3,770.59 | 4,018.48 |
| YOY Revenue Growth % | -4.97% | -27.63% | -9.21% | -4.63% | 7.06% | 35.14% | 6.31% | 0.62% | 76.1% | 15.15% | 15.8% | 23.1% |
| Other Income | 1.70 | 45.41 | 773.17 | 31.49 | 39.42 | 31.13 | 11.69 | 26.44 | 200.63 | 44.47 | 189.08 | 65.76 |
| Total Income | 3,209.07 | 2,552.11 | 3,836.12 | 3,275.68 | 3,473.21 | 3,418.68 | 3,267.89 | 3,290.88 | 6,247.50 | 3,945.08 | 3,959.67 | 4,084.25 |
| Total Expenses + | 3,008.01 | 2,996.77 | 2,858.51 | 2,813.34 | 3,000.64 | 2,962.35 | 2,887.10 | 2,872.07 | 3,894.98 | 3,226.74 | 3,198.50 | 3,440.86 |
| Cost of Materials Consumed | 915.75 | 657.51 | 754.31 | 685.77 | 774.36 | 746.37 | 794.78 | 732.47 | 722.50 | 775.30 | 731.20 | 601.07 |
| Employee Benefit Expense | 732.88 | 753.04 | 700.96 | 710.44 | 786.57 | 788.49 | 736.57 | 762.75 | 1,086.26 | 841.40 | 887.44 | 934.70 |
| Other Expenses | 814.43 | 930.05 | 862.13 | 835.45 | 975.24 | 914.60 | 869.66 | 905.59 | 1,336.56 | 894.37 | 948.27 | 1,033.19 |
| Operating Profit | 199.37 | -490.07 | 204.45 | 430.84 | 433.16 | 425.20 | 369.11 | 392.37 | 2,151.89 | 673.87 | 572.08 | 577.63 |
| OPM % | 6.2% | -19.6% | 6.7% | 13.3% | 12.6% | 12.6% | 11.3% | 12% | 35.6% | 17.3% | 15.2% | 14.4% |
| Profit Before Tax + | -124.36 | -521.38 | 530.83 | 462.33 | 472.57 | 456.33 | 7.97 | 95.58 | 967.40 | 534.00 | 387.77 | 643.39 |
| Tax Expense | -60.80 | -190.57 | 1,745.10 | 122.10 | 118.09 | 108.30 | 3.59 | 48.61 | 356.97 | 130.77 | 86.45 | 160.56 |
| Tax % | - | - | 328.7% | 26.4% | 25% | 23.7% | 45% | 50.9% | 36.9% | 24.5% | 22.3% | 25% |
| Profit After Tax | -63.55 | -330.82 | -1,214.27 | 340.24 | 354.49 | 348.03 | 4.38 | 46.97 | 610.43 | 403.23 | 301.32 | 482.83 |
| EPS (Basic) | -2.90 | -12.45 | -43.18 | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 | 21.63 | 14.29 | 10.68 | 17.11 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 16,982.51 | 13,321.74 | 11,813.10 | 12,990.11 | 12,304.90 | 10,943.93 | 10,640.97 |
| YOY Revenue Growth % | 27.48% | 12.77% | -9.06% | 5.57% | 12.44% | 2.85% | - |
| Other Income | 460.62 | 113.72 | 839.99 | 316.79 | 166.67 | 50.22 | 159.60 |
| Total Income | 17,443.13 | 13,435.46 | 12,653.09 | 13,306.90 | 12,471.58 | 10,994.15 | 10,800.57 |
| Total Expenses + | 13,192.30 | 11,663.43 | 11,715.64 | 11,672.59 | 10,769.42 | 9,656.22 | 7,785.72 |
| Cost of Materials Consumed | 2,961.46 | 3,001.27 | 3,157.82 | 3,593.79 | 3,278.76 | 3,137.81 | 2,541.47 |
| Employee Benefit Expense | 3,577.85 | 3,022.06 | 2,868.14 | 2,780.96 | 2,447.42 | 2,343.71 | 2,254.78 |
| Other Expenses | 4,084.78 | 3,594.96 | 3,336.25 | 3,393.83 | 3,151.90 | 2,817.02 | 2,989.47 |
| Operating Profit | 3,790.21 | 1,658.31 | 97.46 | 1,317.52 | 1,535.49 | 1,287.71 | 2,855.25 |
| OPM % | 22.3% | 12.4% | 0.8% | 10.1% | 12.5% | 11.8% | 26.8% |
| Profit Before Exceptional | 4,250.83 | 1,772.03 | 937.45 | 1,634.31 | 1,702.16 | 1,337.93 | 1,063.20 |
| Exceptional Items | -2,266.08 | -372.82 | -900.96 | -765.85 | -260.91 | 44.55 | 32.88 |
| Profit Before Tax + | 1,984.75 | 1,399.21 | 36.50 | 868.45 | 1,441.25 | 1,382.48 | 1,096.08 |
| Tax Expense | 622.79 | 352.07 | 1,470.02 | 491.05 | 447.60 | 412.39 | 320.11 |
| Tax % | 31.4% | 25.2% | 4028% | 56.5% | 31.1% | 29.8% | 29.2% |
| Profit After Tax | 1,361.95 | 1,047.14 | -1,433.52 | 377.40 | 993.65 | 970.09 | 775.97 |
| EPS (Basic) | 48.26 | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 | 27.50 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Non-Current Assets + | 8,608.17 | 6,754.09 | 6,930.54 | 9,497.96 | 8,800.94 | 8,244.00 | 0.00 |
| Property, Plant & Equipment | 3,889.57 | 3,319.37 | 3,118.15 | 3,904.16 | 3,690.63 | 2,957.78 | 0.00 |
| Capital Work in Progress | 427.87 | 541.99 | 419.32 | 1,115.18 | 921.09 | 1,217.79 | 0.00 |
| Non-Current Investments | 42.36 | 56.36 | 789.66 | 44.65 | 49.62 | 24.63 | 0.00 |
| Goodwill | 82.86 | 70.27 | 67.36 | 73.62 | 60.02 | 58.01 | 0.00 |
| Other Intangible Assets | 1,942.11 | 1,097.19 | 1,024.65 | 2,224.61 | 2,136.60 | 2,113.06 | 0.00 |
| Current Assets + | 11,299.71 | 9,295.47 | 7,428.08 | 9,873.72 | 8,282.35 | 7,359.58 | 0.00 |
| Inventories | 3,430.78 | 3,028.53 | 2,513.05 | 2,977.79 | 2,499.83 | 2,276.83 | 0.00 |
| Trade Receivables | 4,963.35 | 3,341.95 | 1,858.41 | 4,098.61 | 3,101.14 | 2,572.06 | 0.00 |
| Cash and Cash Equivalents | 1,174.71 | 1,675.71 | 1,658.27 | 1,443.03 | 1,410.53 | 1,138.10 | 0.00 |
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| LIABILITIES & EQUITY | |||||||
| Total Equity | 10,511.79 | 8,849.07 | 7,847.55 | 9,839.26 | 9,438.12 | 7,064.27 | 0.00 |
| Equity Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 0.00 |
| Other Equity | 10,483.89 | 8,821.22 | 7,819.71 | 9,445.71 | 9,058.43 | 7,036.41 | 0.00 |
| Non-Current Liabilities | 3,019.66 | 1,233.46 | 692.49 | 4,486.89 | 2,955.74 | 4,338.28 | 0.00 |
| Current Liabilities | 6,376.43 | 5,967.02 | 5,818.59 | 5,045.53 | 4,689.43 | 4,201.02 | 0.00 |
| Total Liabilities | 9,396.08 | 7,200.48 | 6,511.08 | 9,532.42 | 7,645.17 | 8,539.30 | 0.00 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activities | 3,445.03 | -827.60 | -265.44 | 625.39 | 1,108.65 | 1,131.21 | 0.00 |
| Cash from Investing Activities | -1,283.23 | 2.09 | 4,369.14 | -528.49 | -333.28 | -675.24 | 0.00 |
| Cash from Financing Activities | -2,708.75 | 787.05 | -3,906.13 | -77.46 | -520.49 | -441.78 | 0.00 |
| Net Increase/Decrease in Cash | -501.00 | 17.44 | 215.24 | 32.50 | 272.43 | 27.82 | 0.00 |